AlphaCentric Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

AlphaCentric Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-151,000	Closed	-$2.22M	–	230
2023 Q4	$2.22M	Buy	151,000 +5,500	+4%	+$84.3K	1.49%	19
2023 Q3	$2.66M	Buy	145,500 +37,500	+35%	+$793K	1.51%	16
2023 Q2	$2.33M	Buy	108,000 +100,500	+1,340%	+$2.71M	1.29%	16
2023 Q1	$220K	Buy	+7,500	New	+$261K	0.15%	142

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AlphaCentric Advisors's AMLX Position: Q1 2024 in Review

AlphaCentric Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 151,000 shares — an estimated $2.22M sold.

AlphaCentric Advisors first reported a position in AMLX in Q1 2023 and held it in 4 quarters. The position peaked at $2.66M in Q3 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

AlphaCentric Advisors reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AlphaCentric Advisors sold 151,000 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $2.22M.
AlphaCentric Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 4 quarters.
AlphaCentric Advisors's Amylyx Pharmaceuticals position peaked at $2.66M in Q3 2023.
143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on AlphaCentric Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.